What was studied?
This randomized trial studied people with HIV and non-alcoholic fatty liver disease. The primary comparison assessed liver fat after 12 months of tesamorelin or placebo.
What did the researchers report?
The tesamorelin group had a greater reduction in measured liver fat. Localized administration-site complaints were more common, while measured glucose changes did not differ between groups at 12 months.
What are the limits?
This small study does not establish long-term liver outcomes or applicability to everyone with fatty liver. A change in liver fat is not equivalent to proof of preventing cirrhosis or other clinical complications.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.